GSK and ViiV Healthcare are presenting new data across their infectious disease portfolios at IDWeek 2024, showcasing advances in vaccines and treatments for respiratory syncytial virus (RSV), HIV, and urinary tract infections. The presentations include findings from clinical trials and real-world studies, providing insights into efficacy, safety, and patient outcomes.
RSV Vaccine Immunogenicity and Safety
GSK is sharing data on its RSVPreF3 OA vaccine, including the persistence of immunogenicity and safety in adults aged 50-59 years. Additional studies highlight the vaccine's robust immune response across different age ranges and frailty statuses in older adults. Early post-marketing safety surveillance data is also being presented. These findings contribute to the understanding of the vaccine's performance in real-world settings and its potential to protect older adults from RSV-related illness.
HIV Treatment with Cabotegravir and Rilpivirine
ViiV Healthcare is presenting real-world data on the benefits of switching to cabotegravir + rilpivirine long-acting (CAB+RPV LA) from oral antiretroviral therapy (ART) for people living with HIV. The data indicates high adherence and treatment satisfaction among those who switched. Further research explores the use of long-acting cabotegravir/rilpivirine in people living with HIV with renal transplantation, offering insights into treatment options for specific patient populations.
Gepotidacin for Uncomplicated Urinary Tract Infections
GSK is presenting efficacy data for gepotidacin versus nitrofurantoin in uncomplicated urinary tract infections (uUTIs) where nitrofurantoin is not susceptible. Pooled analyses from the EAGLE-2 and EAGLE-3 randomized controlled trials are being presented. In vitro activity of gepotidacin against Klebsiella pneumoniae and Escherichia coli isolates, including those with resistance to other antibacterial agents, is also being highlighted. These findings support the potential of gepotidacin as a treatment option for uUTIs, particularly in the face of increasing antimicrobial resistance.
Long-Acting Cabotegravir for PrEP
Real-world data on long-acting injectable cabotegravir for pre-exposure prophylaxis (PrEP) is being presented, demonstrating promising results regarding on-time dosing, HIV testing, and HIV acquisition rates. Data from the OPERA and Trio Health cohorts provide insights into the use of cabotegravir LA for PrEP in diverse populations. Additional studies explore patient experiences and provider perspectives on integrating cabotegravir LA for PrEP into care, including in community pharmacy settings.
